Kuros Biosciences AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSBTF research report →
About the company
Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics.
- CEO
- Christopher T. Fair
- IPO
- 2014
- Employees
- 122
- HQ
- Schlieren, CH
Price Chart
- Market Cap
- $896.06M
- P/E
- 448.83
- P/S
- 5.82
- P/B
- 11.19
- EV/EBITDA
- 72.80
- Div Yield
- 0.00%
- Gross Margin
- 87.02%
- Op Margin
- 5.99%
- Net Margin
- 1.26%
- ROE
- 2.28%
- ROIC
- 4.00%
- Revenue
- $121.36M · 60.62%
- Net Income
- $2.12M · 157.04%
- EPS
- $0.06 · 155.16%
- Op Income
- $7.33M
- FCF YoY
- -218.57%
- 52W High
- $42.81
- 52W Low
- $22.72
- 50D MA
- $25.33
- 200D MA
- $32.20
- Beta
- 0.74
- Avg Volume
- 57
Get TickerSpark's AI analysis on CSBTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CSBTF coverage
Recent articles, reports, and earnings notes.
No research on CSBTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSBTF report →Similar companies
Peers in the same neighborhood.